News | June 23, 2026
WuXi Biologics wins fourth EMA certification for Suzhou Biosafety Center
Clearing 19 biologics for Europe market
Clearing 19 biologics for Europe market
M&A activity, IPOs and late-stage investments gain momentum as investors prioritize clinical validation, while early-stage biotech firms continue to face funding challenges
First-in-class topical androgen receptor inhibitor marks Glenmark’s first New Chemical Entity (NCE) launch in Europe
The validation confirms the submission is complete, clearing the way for the EMA’s centralized review process to formally evaluate the therapy
Derived from rice bran wax, Licocare RBW products offer a renewable solution with a substantially lower carbon footprint than conventional montan waxes
The approval marks a major milestone in the global fight against antimicrobial resistance
If approved, TEV-‘749 would mark a shift toward long-acting care aimed at improving treatment adherence in real-world settings
The approval was granted by Agenzia Italiana del Farmaco
SFDA nod marks company’s strategic entry into high-value specialty oncology injectables as it targets expanding stem cell transplant and haemato-oncology market in the GCC region
SERB has a substantial European commercial presence and a successful track record in critical care and rare disease commercialization
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
